NEW YORK (GenomeWeb) – US Oncology Network has selected Myriad Genetics Laboratories as its preferred provider of hereditary cancer genetic testing.
Myriad Genetics said it will provide testing through the Genetic Risk Evaluation and Testing (GREAT) program, which will be accessible to 800,000 patients who each year receive care from the more than 1,000 community physicians across 350 sites within US Oncology Network.
As part of GREAT, Myriad and US Oncology Network will create a database linking genetic test results with patients outcomes. "Principal among the research aims of this program is to better understand the genotype-phenotype correlation, gene prevalence, and research related to improving patient counseling and access to testing," the collaborators said in a statement.